HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives $14.87 Consensus Price Target from Brokerages

Posted by on Aug 6th, 2026

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM – Get Free Report) has earned a consensus recommendation of “Hold” from the six research firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $14.8667.

A number of equities research analysts recently commented on HCM shares. Bank of America decreased their price target on HUTCHMED from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. The Goldman Sachs Group decreased their target price on HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a report on Thursday, July 23rd. Weiss Ratings cut HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a report on Friday, July 31st. Finally, Morgan Stanley set a $13.60 price target on shares of HUTCHMED in a research report on Thursday, May 28th.

View Our Latest Research Report on HUTCHMED

HUTCHMED Trading Down 0.2%

Shares of NASDAQ:HCM opened at $11.55 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.50 and a current ratio of 5.64. The company’s fifty day moving average is $10.99 and its 200-day moving average is $13.13. HUTCHMED has a 52 week low of $9.77 and a 52 week high of $18.30.

HUTCHMED (NASDAQ:HCM – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.09). The business had revenue of $139.14 million for the quarter, compared to analysts’ expectations of $304.16 million. On average, equities analysts forecast that HUTCHMED will post 0.23 EPS for the current fiscal year.

Hedge Funds Weigh In On HUTCHMED

A number of large investors have recently modified their holdings of HCM. Goldman Sachs Group Inc. increased its holdings in shares of HUTCHMED by 8.5% in the first quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock valued at $1,413,000 after purchasing an additional 7,342 shares in the last quarter. Jane Street Group LLC raised its position in HUTCHMED by 128.0% in the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after purchasing an additional 124,771 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in HUTCHMED by 4.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after buying an additional 698 shares in the last quarter. Bank of America Corp DE raised its stake in shares of HUTCHMED by 17.3% during the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock worth $310,000 after buying an additional 3,035 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in HUTCHMED by 19.7% during the second quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock worth $377,000 after buying an additional 4,116 shares during the last quarter. 8.82% of the stock is currently owned by institutional investors and hedge funds.

HUTCHMED Company Profile

(Get Free Report)

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.

Featured Stories

Analyst Recommendations for HUTCHMED (NASDAQ:HCM)

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.